Psoriasis
Conditions
Interventions
Treatment with Vunakizumab:Treatment with Vunakizumab
Sponsors
Dematology Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Male or female subjects aged >= 18 years. 2.Subjects meeting the definition of moderate-to-severe psoriasis, specifically: • Psoriasis Area and Severity Index (PASI) score >= 3; • Body Surface Area (BSA) involvement >= 3%. 3.Subjects diagnosed with moderate-to-severe chronic plaque psoriasis who have had an inadequate response to topical therapies, phototherapy, and/or prior systemic treatments.
Exclusion criteria
Exclusion criteria: 1.History of serious infections. 2.Known hypersensitivity to biologic agents or a history of multiple drug allergies. 3.Evidence of active or latent tuberculosis infection indicated by positive T-spot test or chest X-ray, without adequate treatment. 4.Presence of hepatitis B virus (HBV) infection or hepatitis B surface antigen (HBsAg) positivity with significant liver function impairment. 5.History of malignancy. 6.History of substance abuse or psychiatric disorders. 7.Subjects with severe heart failure. 8.Subjects with immunodeficiency. 9.Women who are pregnant, breastfeeding, or planning to conceive in the near future.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psoriasis Area and Severity Index; | — |
Secondary
| Measure | Time frame |
|---|---|
| Body surface area, BSA;Dermatology life quality index, DLQI;Physician's global assessment, PGA; | — |
Countries
China
Contacts
Public ContactYongfeng chen
Dematology Hospital of Southern Medical University
Outcome results
None listed